Ⅱ型固有淋巴细胞与支气管哮喘关系的研究进展

Progress of the relationship between group 2 innate lymphoid cells and bronchial asthma

Ⅱ型固有淋巴细胞(group 2 innate lymphoid cells,ILC2)是新近发现的一类固有免疫细胞亚群,与支气管哮喘(以下简称哮喘)的发生发展密切相关。ILC2是在转录因子视黄酸相关孤儿受体α和GATA结合蛋白3调控下由骨髓中的淋巴祖细胞发育而来。在上皮细胞源性细胞因子IL-25、IL-33、胸腺基质淋巴细胞生成素和脂质递质介导下可产生IL-4、IL-5、IL-9、IL-13等Th2型细胞因子,激活固有免疫细胞和适应性免疫细胞参与哮喘炎症反应。ILC2可能成为哮喘的治疗靶点,为哮喘的预防及治疗提供新的可能。

Group 2 innate lymphoid cells(ILC2)are a newly identified subset of innate immune cells which are closely associated with the development of bronchial asthma(asthma).ILC2 develops from lymphoid progenitor cells in the bone marrow under the regulation of retinoid-related nuclear orphan receptorα(RORα)and GA-TA-binding protein-3(GATA-3).ILC2 can be activated by IL-25,IL-33,thymic stromal lymphopoietin(TSLP)and lipid mediator and produce Th2 cytokines,such as IL-4,IL-5,IL-9 and IL-13,which activate innate immune cells and adaptive immune cells to participate in asthma inflammation.ILC2 may be a therapeutic target for asthma,providing new possibilities for the prevention and treatment.